An American pharmaceutical company, Eli Lilly and Company is headquartered in Indianapolis. The company has locations in over 18 countries. This pharmaceutical giant was founded in 1876. For the treatment of diabetes, Eli Lilly introduced the world’s first commercially available insulin named Iletin. The company sells their products at approx. 125 countries. The company’s major business is in diabetes and other endocrinology products, immunology products, neuroscience products, oncology products, and other products.
Eli Lilly and Company is well known for its clinical depression drugs Prozac (1986), and Cymbalta (2004) as well as antipsychotic medication Zyprexa (1996). Moreover, the great achievement of Eli Lilly and Company is being the notable contributor of the polio vaccine which was made by Jonas Salk. In addition, it was the first company to manufacture insulin from human recombinant DNA, including Humulin (insulin medication), Humalog (insulin lispro), and Basaglar (“insulin glargine”) in the US.
Lilly was the largest corporation in Indiana and the biggest charitable benefactor as of 1997. It was also ranked 123rd in the Fortune 500. It is a full member of both the Pharmaceutical Research and Manufacturers of America and the European Federation of Pharmaceutical Industries and Associations.
The company developed new medicines and made many technological advancements, including the automation of its production lines. Pill capsule manufacturing was another area of innovation for Lilly. Lilly was also the first to insert medication into gelatin capsules. This allowed for more precise dosage.
Other innovations improved plant efficiency and reduced production errors. In the 1920s Eli introduced straight-line production. This means that raw materials enter at one end and the finished product exits the other. Eli was responsible for the design of Building 22, a 5-floor new plant in Indianapolis that opened in 1926. It used the straight-line method to increase production efficiency and reduce production costs.
The FDA revoked an emergency authorization (EUA), which allowed for and signaled FDA consent for bamlanivimab to be administered alone for treatment of mild-to-moderate COVID-19. [120] The company announced that it would purchase Protomer Technologies for more than $1 billion in July 2021. Due to ineffectiveness against the new omicron variant, Lilly’s COVID-19 anti-infective drug was stopped in 2022.
Lilly at a Glance
- Company founded on May 10, 1876, a company with a rich heritage of 145 years
- The headquarters are located in Indianapolis, Indiana, U.S.A.
- Worldwide, there are more than 36,000 employees
- Research and development employs approximately 8,300 people
- More than 55 countries have been involved in clinical research
- Research and development facilities in 7 countries
- Manufacturing plants in 7 countries
- Products are sold in 120 countries
- Research & Development
2021 Expenditures
- $7,026 Million
- ~$28 million/workday
- R&D as a percentage: 25%
- R&D activities are carried out by employees
- 23% of the total workforce
Cost of Pharmaceuticals
- The average cost of developing and discovering a new drug is $2.6 billion
- The average time it takes from patient discovery to the patient is 10 years
Eli Lilly’s Total Revenue By Segment 2016-2021
This graph displays the revenue of Eli Lilly and Company between 2016 and 2021, broken down by segment. Eli Lilly is a top-ranked pharmaceutical company and the largest global manufacturer and distributor of psychotropic medications. Through its oncology division, the company earned 3.03 billion U.S. Dollars in revenue in 2021.
Eli Lilly’s Research and Development Expenditure 2007-2021
This statistic shows the pharmaceutical company Eli Lilly and Company’s research and development spending from 2007 to 2021. Eli Lilly is a top-ranking pharmaceutical company and the largest global manufacturer and distributor of psychotropic medications. Research and development spending reached around 7 billion U.S. Dollars in 2021. Eli Lilly and Company, an international pharmaceutical company, is based in Indianapolis, Indiana.
Eli Lilly Employment Numbers 2013-2021
This timeline shows Eli Lilly’s employees’ numbers from 2013 through 2021. The company had approximately 35 thousand employees in 2021. Eli Lilly is a global leader in pharmaceuticals and the largest distributor and manufacturer of psychiatric medication.
Revenue of Eli Lilly and Company from 2016 to 2021, by Region* (in million U.S. dollars)
This graph displays the revenue of Eli Lilly and Company between 2016 and 2021, separated by region. Eli Lilly is a top-ranking pharmaceutical company and the largest global manufacturer and distributor of psychotropic medications. The company’s revenue from Japan was 2.37 billion U.S. Dollars in 2021.
Eli Lilly’s Total Revenue 2007-2021
This graph shows Eli Lilly and Company’s revenue from 2007 to 2021. Eli Lilly is a top-ranked pharmaceutical company and the largest global distributor and manufacturer of psychiatric medication. The company earned 28.3 Billion U.S. Dollars in revenue in 2021.
Eli Lilly and Company’s Top Products Based on Revenue 2020-2021
Trulicity, which generated about 6.5 billion U.S. Dollars in 2021, was Eli Lilly’s largest revenue generator. Humalog, which generated about 2.5 billion U.S. Dollars in revenue, was the next highest. Eli Lilly, a multinational pharmaceutical company, is based in Indianapolis.
Recent Developments
The Year 2022
- Contracts/Agreements; In January, Eli Lilly and Evotec entered into a drug discovery collaboration in the field of metabolic diseases with a focus on kidney diseases and diabetes.
- Contracts/Agreements; In February, Eli Lilly and Foundation Medicine, Inc. collaborated on the development of Foundation Medicine’s tissue- and blood-based assays as companion diagnostics for RETEVMO and other therapies in Loxo Oncology at Lilly’s pipeline.
- Contracts/Agreements; In January, Eli Lilly and Entos Pharmaceuticals entered into a research and collaboration agreement to develop innovative therapies for a variety of neurologic conditions.
- Financing agreements; In February Eli Lilly announced that the Lilly Institute for Genetic Medicine was being launched. A US$700 million investment was made to create a state-of-the-art facility on a new site at the Boston Seaport.
The Year 2021
- Contracts/Agreements; In January, the company and Blacksmith entered into a research collaboration to combine Blacksmith’s innovative chemistry platform with its research and development expertise for novel human metalloenzyme-targeted medicines.
- Contracts/Agreements; In January, Eli Lilly’s subsidiary, Loxo Oncology, and Merus entered into a research collaboration to develop up to three CD3-engaging T-cell redirecting bispecific antibody therapies.
- Contracts/Agreements; In January, Eli Lilly along with GlaxoSmithKline, and Vir Biotechnology entered into a collaboration to evaluate the combination of bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19.
- Contracts/Agreements; In February, Eli Lilly entered into a partnership with Area Health Systems to launch dedicated infusion centers for COVID-19 patients.
- Contracts/Agreements; In February, Eli Lilly and Iterative Scopes entered into a partnership to advance AI applications for inflammatory bowel disease clinical trials.
- Contracts/Agreements; In February, Eli Lilly and the University of Glasgow entered into a research collaboration to develop the next generation of drug targets for immunological diseases.
- Contracts/Agreements; In February, Eli Lilly and Rigel Pharmaceuticals entered into an agreement to co-develop receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitors to treat neurodegenerative diseases.
- Contracts/Agreements; In February, Eli Lilly entered into a collaboration and licensing agreement with Welldoc to integrate Welldoc’s software into Lilly’s connected insulin services, currently in development.
- Contracts/Agreements; In March, the company entered into a research collaboration and license agreement with Biolojic Design Ltd to discover and develop a potential novel antibody-based therapy for the treatment of diabetes.
- Contracts/Agreements; In May, Eli Lilly entered into agreements with DexCom Inc, Glooko Inc, myDiabby Healthcare, and Roche to integrate connected insulin pen solutions for people with diabetes.
- Contracts/Agreements; In May, Eli Lilly and MiNA Therapeutics entered into a research collaboration to develop therapies using MiNA’s small activating RNA technology platform.
- Contracts/Agreements; In May, Eli Lilly and Natco Pharma signed a licensing agreement for baricitinib use in India to treat Covid-19.
- Contracts/Agreements; In May, Eli Lilly and Arecor Limited entered into a formulation study partnership to develop proprietary products intended for self-administration by using Arecor’s s proprietary formulation technology platform Arestat.
- Contracts/Agreements; In June, the company and ALX Oncology entered into a clinical trial collaboration and supply agreement to evaluate the combination of its ALX148 with Lilly’s anti-VEGFR2 antibody, CYRAMZA to treat people with gastric cancer or gastroesophageal junction cancer.
- Regulatory Approval. In June, Eli Lilly’s investigational anti-inflammatory therapy, donanemab, was granted the breakthrough therapy designation by the FDA to treat Alzheimer’s disease patients.
- Contracts/Agreements; In July, Eli Lilly and Verge Genomics signed a three-year collaboration to develop novel therapies for the treatment of amyotrophic lateral sclerosis.
- Acquisitions/Mergers/Takeovers; In July, Eli Lilly announced the acquisition of Protomer Technologies, a biotech company for US$1 billion.
- Contracts/Agreements; In July, Eli Lilly and Banner Alzheimer’s Institute entered into a research partnership to conduct the planned Phase III TRAILBLAZER-ALZ 3 clinical trial of donanemab.
- Asset Disposal. In July, Eli Lilly sold Cialis in China to A. Menarini Asia-Pacific Holdings Pte. Ltd.
- Contracts/Agreements; In August, Eli Lilly entered into a partnership with Lycia Therapeutics, Inc. to develop and commercialize novel targeted therapeutics using Lycia’s proprietary lysosomal targeting chimera.
- Regulatory approval; In August, Eli Lilly and Boehringer Ingelheim obtained the US FDA approval of Jardiance for adults with heart failure. Jardiance is a treatment that reduces the ejection fraction.
- Regulatory approval; In August, Eli Lilly received approval from the USFDA to market its Lyumjev insulin for adults.
- Contracts/Agreements; In August, Eli Lilly and Lycia Therapeutics entered into a multi-year research partnership and licensing agreement to discover, develop and market new targeted therapeutics.
- Contracts/Agreements; In July, Eli Lilly entered into a research collaboration with AlphaMa Biotech to utilize AlphaMa’s proprietary intelligent DNA-encoded libraries for drug development in selected therapeutic areas.
- Regulatory Approval. In October, Eli Lilly was approved by the US Food and Drug Administration for Verzenio (abemaciclib), which is used to treat HR+ HER2- high-risk early breast cancer patients.
Participation of Lilly in Publicly Funded Research
Lilly also participates in public-funded research projects with academic and industrial partners. One example in the area of non-clinical safety assessment is the InnoMed PredTox, a collaboration with pharmaceutical companies, research organizations, and the European Commission to improve the safety of drugs. In 2008 this consortium, which included Lilly S.A. (Switzerland), secured a EUR8 million budget for a 40-month project that was coordinated by the European Federation of Pharmaceutical Industries and Associations (EFPIA), an organization that represents the research-based pharmaceutical industry and biotech companies operating in Europe. In 2008 Lilly’s activities included research projects within the framework of the Innovative Medicines Initiative, a public-private research initiative in Europe that is a joint effort of the EFPIA and the European Commission.
